Related references
Note: Only part of the references are listed.A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
R. K. Russell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
Gert Van Assche
GUT (2011)
Improvement in Growth of Children With Crohn Disease Following Anti-TNF-alpha Therapy Can Be Independent of Pubertal Progress and Glucocorticoid Reduction
S. Malik et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2011)
Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study
Francis Vasseur et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Appraisal of the Pediatric Crohn's Disease Activity Index on Four Prospectively Collected Datasets: Recommended Cutoff Values and Clinimetric Properties
Dan Turner et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Effects of Long-Term Etanercept Treatment on Growth in Children With Selected Categories of Juvenile Idiopathic Arthritis
Edward H. Giannini et al.
ARTHRITIS AND RHEUMATISM (2010)
Adalimumab Treatment in Children with Refractory Crohn's Disease
Yoram Rosenbach et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease
Daniel M. Sinitsky et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Oropharyngeal and Proximal Esophageal Involvement During Adalimumab Treatment of Crohn Disease
Kim-Doan Katrina Nguyen et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2010)
Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis
An D. Billiau et al.
RHEUMATOLOGY (2010)
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease
Joel R. Rosh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
Franca Viola et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients
A. Diamanti et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Growth Abnormalities Persist in Newly Diagnosed Children With Crohn Disease Despite Current Treatment Paradigms
Marian Pfefferkorn et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Adalimumab treatment in infliximab resistant pediatric patient with Crohn’s disease
Gábor Veres et al.
ORVOSI HETILAP (2009)
Improvement in Biomarkers of Bone Formation During Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study
Meena Thayu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Short-term Response to Adalimumab in Childhood Inflammatory Bowel Disease
Joshua D. Noe et al.
INFLAMMATORY BOWEL DISEASES (2008)
Safety and efficacy of adalimumab in pediatric patients with Crohn disease
Matthew J. Wyneski et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2008)
The use of adalimumab in the management of refractory Crohn's disease
G. -T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Meta-analysis: enteral nutrition in active Crohn's disease in children
P. Dziechciarz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease
Thomas D. Walters et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial
J. Hinojosa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation
S. C. Wong et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Infliximab dependency in a national cohort of children with Crohn's disease
V Wewer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2006)
Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease
S Mian et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2005)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
O Borrelli et al.
DIGESTIVE AND LIVER DISEASE (2004)
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease
JP Cezard et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2003)
Share Paper
